🔗 Share this article New Antimicrobials Celebrated as a 'Major Shift' in Combating Antibiotic-Resistant Gonorrhea The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to health experts. A Worldwide Health Concern Cases of gonorrhoea are on the rise worldwide, with estimates suggesting more than 82 million new cases per year. Particularly high rates are reported in the African continent and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014. “The approval of new treatments for gonorrhoea is an important and timely development in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.” Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024. A Pair of Novel Treatment Options Gain Approval One new antibiotic, also known as a brand name, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts believe that focused deployment of this new drug will help hinder the development of resistance. Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria. A Novel Approach to Creation Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition. “This approval represents a significant shift in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.” Research Study Data and Global Access As per findings published in a major medical journal, zoliflodacin eradicated more than 90% of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which uses two antibiotics. The trial involved hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations. Under the terms of its collaboration, GARDP has the rights to license and sell the drug in a wide range of developing nations. Medical professionals directly involved have expressed hope. Access to a single-dose, oral treatment such as this is seen as a "critical tool" for public health efforts. This is viewed as essential to reduce the burden of the infection for patients and to stop the proliferation of untreatable gonorrhoea worldwide.